Droxidopa for OH

Status: Recruiting

Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effect of Droxidopa Therapy. Dr. Kaufmann is the Principal Investigator and has conducted the original seminal trials of droxidopa, a norepinephrine precursor drug, for the treatment of orthostatic hypotension. In the near future, we hope to begin the next study of droxidopa to determine its long-term effects in the management of orthostatic hypotension in chronic autonomic failure. http://clinicaltrials.gov/show/NCT01927055

Eligibility: The study is open to adults with neurogenic orthostatic hypotension.

IRB#: S14-00063

Sponsor: Lundbeck